These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31699373)

  • 21. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy.
    Au CG; Butler TL; Sherwood MC; Egan JR; North KN; Winlaw DS
    Int J Exp Pathol; 2011 Feb; 92(1):57-65. PubMed ID: 21121985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
    Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
    J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice.
    Nakae Y; Stoward PJ; Kashiyama T; Shono M; Akagi A; Matsuzaki T; Nonaka I
    J Mol Histol; 2004 Jun; 35(5):489-99. PubMed ID: 15571326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).
    Fukushima K; Nakamura A; Ueda H; Yuasa K; Yoshida K; Takeda S; Ikeda S
    BMC Musculoskelet Disord; 2007 Jun; 8():54. PubMed ID: 17598883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative damage to urinary proteins from the GRMD dog and mdx mouse as biomarkers of dystropathology in Duchenne muscular dystrophy.
    Terrill JR; Al-Mshhdani BA; Duong MN; Wingate CD; Abbas Z; Baustista AP; Bettis AK; Balog-Alvarez CJ; Kornegay JN; Nghiem PP; Grounds MD; Arthur PG
    PLoS One; 2020; 15(10):e0240317. PubMed ID: 33031394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles.
    Kherif S; Lafuma C; Dehaupas M; Lachkar S; Fournier JG; Verdière-Sahuqué M; Fardeau M; Alameddine HS
    Dev Biol; 1999 Jan; 205(1):158-70. PubMed ID: 9882504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suramin affects metalloproteinase-9 activity and increases β-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse.
    Taniguti AP; Matsumura CY; Rodrigues-Simioni L; Santo Neto H; Marques MJ
    Muscle Nerve; 2012 Nov; 46(5):810-3. PubMed ID: 23055317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of chronic treatment with gold nanoparticles on inflammatory responses and oxidative stress in Mdx mice.
    Haupenthal DPDS; Possato JC; Zaccaron RP; Mendes C; Rodrigues MS; Nesi RT; Pinho RA; Feuser PE; Machado-de-Ávila RA; Comim CM; Silveira PCL
    J Drug Target; 2020 Jan; 28(1):46-54. PubMed ID: 31046473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
    Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
    Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
    Wellner G; Mordechay S; Evans P; Genin O; Pines M; Halevy O
    Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute AT
    Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
    J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
    Greco S; De Simone M; Colussi C; Zaccagnini G; Fasanaro P; Pescatori M; Cardani R; Perbellini R; Isaia E; Sale P; Meola G; Capogrossi MC; Gaetano C; Martelli F
    FASEB J; 2009 Oct; 23(10):3335-46. PubMed ID: 19528256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural disease history of the D2
    van Putten M; Putker K; Overzier M; Adamzek WA; Pasteuning-Vuhman S; Plomp JJ; Aartsma-Rus A
    FASEB J; 2019 Jul; 33(7):8110-8124. PubMed ID: 30933664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.